150 related articles for article (PubMed ID: 38443329)
61. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
Sue S; Ogushi M; Arima I; Kuwashima H; Nakao S; Naito M; Komatsu K; Kaneko H; Tamura T; Sasaki T; Kondo M; Shibata W; Maeda S
Helicobacter; 2018 Apr; 23(2):e12456. PubMed ID: 29271026
[TBL] [Abstract][Full Text] [Related]
62. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
[TBL] [Abstract][Full Text] [Related]
63.
Qu P; Liu X; Xia X; Xie X; Luo J; Cheng S; Chi J; Liu P; Li H; Zhao W; Yang H; Xu C
Front Cell Infect Microbiol; 2022; 12():903002. PubMed ID: 35880079
[TBL] [Abstract][Full Text] [Related]
64. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T
Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
[TBL] [Abstract][Full Text] [Related]
65. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
66. Third-line and rescue therapy for refractory
de Moraes Andrade PV; Monteiro YM; Chehter EZ
World J Gastroenterol; 2023 Jan; 29(2):390-409. PubMed ID: 36687120
[TBL] [Abstract][Full Text] [Related]
67. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
[TBL] [Abstract][Full Text] [Related]
68. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
[TBL] [Abstract][Full Text] [Related]
69. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
70. Update on the second-line treatment of
Shih CA; Shie CB; Tai WC; Chuah SK; Lee HC; Hsu PI
Therap Adv Gastroenterol; 2023; 16():17562848231192750. PubMed ID: 37675247
[TBL] [Abstract][Full Text] [Related]
71. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
Choe JW; Jung SW; Kim SY; Hyun JJ; Jung YK; Koo JS; Yim HJ; Lee SW
Helicobacter; 2018 Apr; 23(2):e12466. PubMed ID: 29369454
[TBL] [Abstract][Full Text] [Related]
72. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs.
Gao W; Zhu M; Yin Y; Zhang X; Wang L
Helicobacter; 2023 Dec; 28(6):e13022. PubMed ID: 37839018
[TBL] [Abstract][Full Text] [Related]
74. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Kajihara Y; Shimoyama T; Mizuki I
Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
[TBL] [Abstract][Full Text] [Related]
75. Second-line rescue treatment of
Lin TF; Hsu PI
World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
[TBL] [Abstract][Full Text] [Related]
76. Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection.
Shinmura T; Adachi K; Yamaguchi Y; Izawa S; Hijikata Y; Ebi M; Funaki Y; Ogasawara N; Sasaki M; Kasugai K
J Gastrointestin Liver Dis; 2019 Dec; 28(4):389-395. PubMed ID: 31826057
[TBL] [Abstract][Full Text] [Related]
77. Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial.
Hsu PI; Tsay FW; Graham DY; Tsai TJ; Tsai KW; Kao JY; Peng NJ; Kuo CH; Kao SS; Wang HM; Lin TF; Wu DC;
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1427-1433. PubMed ID: 29609070
[TBL] [Abstract][Full Text] [Related]
78. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Lu B; Wang J; Li J; Liu L; Chen Y
Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
[TBL] [Abstract][Full Text] [Related]
79. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
[TBL] [Abstract][Full Text] [Related]
80. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]